TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16713439
Drug: voglibose (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: voglibose (0.9 mg daily)
Study: 17152785
Drug: Immunosuppressive/anti-inflammatory therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive/anti-inflammatory therapy
Study: 8556998
Drug: Rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.9 mg kg‐1 after 45 s
Study: 8556998
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 after 45 s
Study: 8556998
Drug: Rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.9 mg kg‐1 after 60 s
Study: 8556998
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg‐1 after 60 s
Study: 6104255
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with propranolol and prazosin
Study: 25752357
Drug: 10-day hybrid
Normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day hybrid regimen (PACT-10): pantoprazole 40 mg, amoxicillin 1 g, both twice daily for 10 days; plus clarithromycin 500 mg and tinidazole 500 mg, both twice daily for the last 5 days
Study: 25752357
Drug: 14-day hybrid
Normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day hybrid regimen (PACT-14): pantoprazole 40 mg, amoxicillin 1 g, both twice daily for 14 days; plus clarithromycin 500 mg and tinidazole 500 mg, both twice daily for the last 7 days
Study: 23298898
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral misoprostol and double‐balloon catheter
Study: 8986678
Drug: Oxidized regenerated
Normalized name: Collagen/Oxidized Regenerated Cellulose 55%-45% Topical application Dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxidized regenerated cellulose plus heparin (1,000 U/mL)
Study: 8490772
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone injection along with oral placebo treatment (Group B)
Study: 8490772
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone by a tapering schedule associated with placebo intramuscular injection (Group C)
Study: 8490772
Drug: Intramuscular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular and oral placebos (Group A)
Study: 8490772
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone injection (Group B)
Study: 8490772
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone by a tapering schedule (Group C)
Study: 3814462
Drug: Nimodipine 60
Normalized name: nimodipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 60 mg p.o.
Study: 3814462
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg s.l.
Study: 23523158
Drug: Percutaneous transluminal
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous transluminal angioplasty (PTA) in addition to medical therapy
Study: 23523158
Drug: Delayed PTA
Normalized name: Achillea ptarmica whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed PTA after 6 months of medical therapy alone
Study: 20109997
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 15 mg TID (up to 90 mg/d if needed)
Study: 20109997
Drug: Oxybutynin hydrochloride
Normalized name: Oxybutynin hydrochloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin hydrochloride 2.5 mg TID (up to 15 mg/d if needed)
Study: 16424716
Drug: Novel repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel repeated pulse treatment with methylprednisolone (1 g/day for 3 days) and cyclophosphamide (15 mg/kg/day for 2 days), followed by dexamethasone 20 mg/day until Pao2 was >11.5 kPa, and repeated pulse therapy if Pao2 was <8.64 kPa
Study: 9578184
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three proton pump inhibitors
Study: 7865644
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (75 mg, 300 mg, enteric coated 300 mg)
Study: 2475678
Drug: Chronic verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic verapamil treatment
Study: 770079
Drug: Azapropazone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azapropazone 1200 mg per day before food
Study: 23548832
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus Virtual Reality Exposure Therapy (VRET)
Study: 23548832
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus Exposure in Vivo
Study: 21741331
Drug: 4g/L of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g/L of ascites removed (group 1)
Study: 21741331
Drug: 8g/L of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8g/L of ascites removed (group 2)
Study: 19201586
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate 300 mg/day for 5 weeks (group 1)
Study: 16636211
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss and exercise therapy (6 months of weekly behavioral therapy for weight loss + exercise training 3 times per week)
Study: 16636211
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss and exercise therapy
Study: 15499509
Drug: Disease management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease management programme (DMP) based on weekly telephone monitoring by a case manager
Study: 11092233
Drug: New weight-reducing
Approvals — FDA: no, EMA: no, PMDA: no
Description: New weight-reducing agent based on natural ingredients
Study: 9091835
Drug: Seaprose S
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seaprose S (30 mg tablets, 90 mg daily for 14 days)
Study: 9091835
Drug: Serratio-peptidase (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratio-peptidase (5 mg tablets, 30 mg daily for 14 days)
Study: 1334101
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran (10.3 g beta-glucan/day)
Study: 25647168
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group received a $110 voucher for smoking cessation pharmacotherapy and were registered to an automated calling system.
Study: 25647168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received standard care including smoking cessation advice, a brochure, and a prescription for smoking cessation medication if requested.
Study: 24029535
Drug: Telephone-administered cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive-behavioural therapy (telephone CBT)
Study: 21631542
Drug: gabapentin and
Normalized name: Gabapentin and mecobalamin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: gabapentin and flumazenil combination
Study: 19483295
Drug: Routine dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine dosage fosinopril (10 mg once daily)
Study: 19483295
Drug: Middle dosage
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle dosage fosinopril (10 mg twice a day)
Study: 10639191
Drug: Finasteride (5alpha-reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5alpha-reductase inhibitor) for 6 days to 6 years
Study: 9253234
Drug: Clinical data
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical data used to build a predictive model based on 21 variables including age, absence of previous similar episodes, weight loss, rectal bleeding, lack of improvement, and presence of a mass on digital rectal examination.
Study: 31837959
Drug: Alisertib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (30 mg orally twice per day on days 8-15) combined with 7+3 induction chemotherapy (continuous infusion of cytarabine 100 mg/m2 per day on days 1-7 and intravenous bolus of idarubicin 12 mg/m2 per day on days 1-3)
Study: 31837959
Drug: 7+3 induction
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7+3 induction chemotherapy (cytarabine and idarubicin)
Study: 29735965
Drug: Mild moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild moxibustion at bilateral Shenshu (BL23) for 15 min daily, for 4 courses (5 days each with 2 days between courses)
Study: 29735965
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E soft capsules for 28 days
Study: 28079918
Drug: Lamivudine daily
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine daily oral dose 60-300 mg (3.9-17.6 mg kg-1)
Study: 28079918
Drug: Lamivudine daily
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine daily oral dose 8-10 mg kg-1 day-1 for children <14 kg
Study: 18312874
Drug: Radiofrequency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency treatment (all generators)
Study: 10945508
Drug: Cefdinir 100
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 100 mg BID
Study: 8973979
Drug: ConA (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ConA (1.25 micrograms/ml, 2.5 micrograms/ml, and 5.0 micrograms/ml)
Study: 1478135
Drug: Active music
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active music therapy provided every day for 8 weeks
Study: 1478135
Drug: Antidepressive drugs
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressive drugs (same for both groups)
Study: 1478135
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (active music therapy + antidepressive drugs)
Study: 1478135
Drug: Active music
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active music therapy
Study: 6420374
Drug: 1-2 units
Normalized name: varicella-zoster immune globulin
DrugBank: Human varicella-zoster immune globulin (DB11621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 units insulin/kg body weight/24 h with feed
Study: 6420374
Drug: Feed only
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feed only (no insulin)
Study: 26562292
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice (PC) antiemetic therapy
Study: 22282552
Drug: Zephyr® EBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zephyr® EBV treatment
Study: 18331610
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily for 12 weeks
Study: 15760403
Drug: Doxorubicin chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin chemotherapy (15 mg/m2 biweekly pre-operatively, single dose intra-operatively, total dosage of 300 mg/m2 post-operatively)
Study: 15760403
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (transplanted only, no chemotherapy)
Study: 9669632
Drug: Cisapride, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 5 mg three times daily (n = 19)
Study: 2926468
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 5-FU administered 24 hours a day for a protracted time (10 weeks or more)
Study: 2926468
Drug: Daily bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bolus dose of 5-FU administered intravenously for five consecutive days and repeated at 5-week intervals
Study: 26209642
Drug: Control (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (not specified, but implied as the alternative treatment)
Study: 19139031
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (Diane(35)Diario) - 35 microg ethinyl-estradiol plus 2 mg cyproterone acetate
Study: 19139031
Drug: Metformin -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin - 850 mg twice daily
Study: 17713165
Drug: At 24
Normalized name: FENTANYL 40MCG/ACTUAT 24HR ION SYSTEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 24 weeks post-treatment
Study: 15126801
Drug: Medical castration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical castration with a luteinizing hormone releasing hormone analogue
Study: 8295585
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine therapy
Study: 29650363
Drug: Chemotherapy (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (3 preoperative cycles and 3 postoperative cycles of intravenous epirubicin, cisplatin or oxaliplatin, and capecitabine)
Study: 29650363
Drug: Chemoradiotherapy (preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (preoperative chemotherapy followed by 45 Gy in 25 fractions of radiotherapy combined with capecitabine and cisplatin)
Study: 28836960
Drug: Five weekly
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five weekly sessions of psychosocial intervention combined with early palliative care (Arm A)
Study: 28836960
Drug: Standard cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cancer treatment (Arm C)
Study: 2323085
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic (gentamicin sulphate)
Study: 2323085
Drug: Topical antiseptic
Normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL GEL [Germ Free Topical Antiseptic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiseptic (aluminium acetate)
Study: 223950
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid therapy for 5 days
Study: 223950
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid therapy for 10 days
Study: 223950
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid therapy for 15 days
Study: 31626696
Drug: Phentermine HCl
Normalized name: phentermine HCl
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentermine HCl 60 mg
Study: 31626696
Drug: Pitolisant 35.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitolisant 35.6 mg
Study: 31626696
Drug: Pitolisant 213.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitolisant 213.6 mg
Study: 28277845
Drug: New mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: New mometasone furoate cream
Study: 28277845
Drug: Positive control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive control (marketed Elocon cream)
Study: 25586724
Drug: sugammadex 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugammadex 1.0 mg kg(‐1)
Study: 22751847
Drug: Fingolimod, 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod, 1.25 mg
Study: 22354739
Drug: Fingolimod (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (both doses)
Study: 21375019
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for 30 min, once daily for 4 weeks.
Study: 21375019
Drug: Mecobalamine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecobalamine (500 microg) intramuscular injection, once daily for 4 weeks.
Study: 21375019
Drug: Mecobalamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecobalamine treatment
Study: 17699944
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 200 mg once daily for three days
Study: 17699944
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 250 mg/six-hourly for three days followed by oral prednisolone for 11 days
Study: 16045572
Drug: High-dose-rate endoluminal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate endoluminal brachytherapy (7 Gy x 3 given in 2-4 weeks)
Study: 10429771
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dolasetron orally 45‐60 minutes before anaesthesia
Study: 10429771
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg i.v. DHB + placebo p.o. (positive control group)
Study: 10429771
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dolasetron orally 45‐60 minutes before anaesthesia and 2.5 mg i.v. DHB during anaesthesia
Study: 10429771
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet administered 45‐60 minutes before anaesthesia (negative control group)
Study: 8680536
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice daily for 6 weeks
Study: 8680536
Drug: Double-therapy (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-therapy (300 mg amoxicillin granules and 250 mg metronidazole thrice daily for 2 weeks + cimetidine)
Study: 6432001
Drug: Niludipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niludipine (20 mg)
Study: 6432001
Drug: Nifedipine (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (chronic administration)
Study: 6432001
Drug: Niludipine (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niludipine (chronic administration)
Study: 30885134
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (2 mg/kg bolus followed by 1.5 mg/kg/h infusion)
Study: 30885134
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (0.5 μg/kg bolus followed by 0.4 μg/kg/h infusion)
Study: 24477319
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of parathyroid hormone (PTH) for 6 weeks
Study: 24477319
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (standard care)
Study: 19123156
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with EPA (720 mg/day) and DHA (480 mg/day) for 6 months
Study: 17242426
Drug: Atomoxetine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.2 mg/kg daily for 3 weeks)
Study: 15970715
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose heparin (600 U/kg)
Study: 15970715
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (300 U/kg)
Study: 7895538
Drug: Pure fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure fat meal (25 g triglycerides)
Study: 7895538
Drug: Mixed meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meal (8 g fat, 10 g protein, 32 g dextrose)
Study: 7895538
Drug: Fat-free meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-free meal (25 g albumin, 32 g dextrose)
Study: 2403903
Drug: Iodinated glycerol
Normalized name: iodinated glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodinated glycerol (Organidin), 60 mg qid
Study: 79028
Drug: Intravenous cholangiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cholangiography (I.V.C.)
Study: 27515478
Drug: pPDT (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pPDT (placebo photodynamic therapy)
Study: 26077585
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents with thrombus aspiration
Study: 16563810
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with additional brace treatment
Study: 16563810
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment alone
Study: 15283826
Drug: Dexamethasone (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (50, 100, 150 microg x kg(‐1), maximum dose 8 mg) with ondansetron (50 microg x kg(‐1))
Study: 11739137
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 microg/d (constant dose approach)
Study: 8424427
Drug: Lymphoblastoid alpha-interferon
Normalized name: interferon alfa-n1 lymphoblastoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid alpha-interferon (L-IFN)
Study: 28735368
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg) as pre-treatment